News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Trius Therapeutics (TSRX) Completes Enrollment in Second Phase 3 Trial of Tedizolid for Skin and Skin Structure Infections



12/10/2012 9:08:34 AM

SAN DIEGO, Dec. 10, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery and development of innovative antibiotics for life-threatening infections, announced today that it has reached its enrollment objective of 658 patients in the last of its two Phase 3 clinical trials of tedizolid phosphate (TR-701) for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES